Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 13/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 13/20 | 1.00 |
| ▸ | PKM | P14618 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 0.76 |
| ▸ | DDX3X | O00571 | 5/20 | 0.75 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12008609 | 0.90 | KMT2A (0.82) | MEN1KMT2APKMPOLBDDX3X | |
| SCHEMBL11913682 | 0.88 | MEN1 (0.79) | MEN1KMT2APKMPOLBDDX3X | |
| SCHEMBL18545481 | 0.86 | MEN1 (0.79) | MEN1KMT2APKMPOLBDDX3X | |
| SCHEMBL12008612 | 0.86 | MEN1 (0.88) | MEN1KMT2APKMPOLBDDX3X | |
| SCHEMBL12008610 | 0.86 | MEN1 (1.00) | MEN1KMT2APKMPOLBDDX3X | |
| SCHEMBL12008611 | 0.85 | KMT2A (0.77) | MEN1KMT2APKMPOLBHIF1AN | |
| SCHEMBL11913691 | 0.84 | MEN1 (0.89) | MEN1KMT2APKMPOLBDDX3X | |
| SCHEMBL12008608 | 0.83 | KMT2A (0.76) | MEN1KMT2APKMPOLBDDX3X | |
| SCHEMBL12008756 | 0.81 | CTNNB1 (0.82) | MEN1KMT2APKMPOLBHIF1AN | |
| SCHEMBL12008994 | 0.81 | MEN1 (1.00) | MEN1KMT2APKMPOLBDDX3X |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202814-A1 | COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF | UNIVERSITÀ DEGLI STUDI DI SIENA (IT) | 2012-08-09 | — | — | US | disclosed |
| WO-2011039735-A2 | COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202814-A1 | COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF | DDX3X, DDX21, DDX39B | MEN1 1855/4885KMT2A 2610/4885PKM 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.